Rigel Pharmaceuticals is a commercial-stage biotech focused on hematology and oncology. Rigel sells three FDA-approved oral drugs in the US. TAVALISSE (fostamatinib) is Rigel's flagship product, approved for chronic immune thrombocytopenia (ITP), a blood disorder where the immune system destroys platelets. TAVALISSE is the only approved oral SYK inhibitor for ITP and is used in adult patients who have not responded adequately to prior treatments. GAVRETO (pralsetinib), acquired from Blueprint Medicines in early 2024, is a once-daily oral RET kinase inhibitor approved for metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer. REZLIDHIA (olutasidenib), in-licensed in 2022, is an oral IDH1 inhibitor approved for relapsed or refractory acute myeloid leukemia with an IDH1 mutation. All three products are sold in the US through wholesale distribution and specialty pharmacy channels, targeting hematologists and oncologists. Rigel also licenses ex-US rights to regional partners and earns royalties and milestones on their sales. Rigel runs a lean organization with a single integrated commercial infrastructure serving all three products, generating operating leverage as it adds products to its existing salesforce. Rigel's pipeline includes R289, an oral dual IRAK1/4 inhibitor in Phase 1b for lower-risk MDS. Rigel's stated growth strategy combines growing its existing commercial portfolio, advancing its pipeline, and acquiring or in-licensing additional late-stage hematology and oncology assets.